|GRANTWAY
EN

Developing a Data Quality and Utility Label for the European Health Data Space

European Comission

Share
Favorite
Feedback
Summary
12 January 2023
13 April 2023
-
-
-
For profit
Individuals
Not for profit (incl. NGOs)
Public sector
R&D and Higher Education
Afghanistan
Albania
Algeria
Angola
Argentina
Armenia
Aruba
Austria
Azerbaijan
Bangladesh
Belarus
Belgium
Belize
Benin
Bhutan
Bolivia
Bonaire
Bosnia and Herzegovina
Botswana
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Cape Verde
Central African Republic
Chad
Colombia
Comoros
Costa Rica
Croatia
Cuba
Curaçao
Cyprus
Czechia
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Faroe Islands
Fiji
Finland
France
French Polynesia
French Southern and Antarctic Territories
Gabon
Gambia
Georgia
Georgia
Germany
Ghana
Greece
Greenland
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Lithuania
Luxembourg
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Micronesia
Moldova
Mongolia
Montenegro
Morocco
Mozambique
Myanmar
Namibia
Nepal
Netherlands
New Caledonia
Nicaragua
Niger
Nigeria
North Korea
North Macedonia
Norway
Pakistan
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Republic of Côte d'Ivoire
Republic of the Congo
Romania
Rwanda
Saba
Saint Barthélemy
Saint Lucia
Saint Vincent and the Grenadines
Samoa
Sao Tome and Principe
Senegal
Serbia
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
St. Eustatius
St. Pierre and Miquelon
Sudan
Suriname
Sweden
Syria
Tajikistan
Tanzania
Thailand
Togo
Tonga
Tunisia
Turkey
Turkmenistan
Tuvalu
Uganda
UK
Ukraine
Uzbekistan
Vanuatu
Venezuela
Vietnam
Wallis and Futuna
Yemen
Zambia
Zimbabwe
Research, Development and Innovation Natural Sciences
Overview

ExpectedOutcome :

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed towards and contributing to all of the following expected outcomes:

  • Data Users (researchers, innovators, regulators, policymakers, clinicians) are able to identify the most relevant datasets that meet their specific needs through a label describing accurately and in a standard way the quality and utility dimensions of the datasets, as proposed in the legal provisions of the European Health Data Space (EHDS).
  • Data holders have clear specifications for dataset quality and utility labelling to comply with the requirements proposed in the EHDS legal provisions. In addition to that, data holders have access to a maturity model with the requirements a dataset needs to fulfil to achieve higher levels of data quality and utility.
  • European and National public funders ensure that the datasets, for which they provided funding for the creation and curation of, are more widely available, furthering their reuse for secondary uses as proposed in the EHDS legal provisions (research, innovation, regulatory work, policymaking, personalised medicine).
  • The European Commission has access to a set of specifications for the data quality and utility label supporting the implementation of the EHDS legal provisions. Scope :

A vast quantity of health datasets exist across Europe, from multiple sources (individual care, medical registries, social, environmental behavioural, wellbeing, clinical trials, research, administrative, etc.), and of varying quality. This represents a tremendous opportunity for the reuse of this data for purposes other than for the one for which they were originally collected and spur the development of better prevention strategies, diagnoses, treatments and care plans.

The European Health Data Space (EHDS) will provide a common EU framework for secondary use of health data such as research, innovation, regulatory purposes, policymaking and personalised medicine. It will enable data users to have access to large amounts of health data through health data access bodies empowered with the EHDS legal provisions to overcome existing limitations regarding the processing of health data for secondary uses.

To support data users in the discovery and selection of datasets for their purposes, there is a growing need to develop a data quality and utility framework to articulate the characteristics and the potential usefulness of datasets. This framework will also support data holders in identifying and addressing areas of improvement which can, in turn, allow for wider and better use of these datasets.

Several initiatives have developed or are developing guidelines and recommendations for health data quality, however, these typically focus on specific data types (i.e. 1+ Million Genome Initiative[1]) or areas of applications (i.e. European Medicines Agency – EMA and Heads of Medicines Agencies’ Big Data Steering Group activities to support medicines regulation[2]). Similarly, previous studies and initiatives have addressed specific dimensions of ‘data quality’ for health data but none are offering a framework suitable for the breadth of data types and encompassing the quality and utility elements proposed in the EHDS legal provisions. The proposed framework should take into account the various needs of data users whilst at the same time avoid becoming an excessive burden on data holders which will need to produce the data quality and utility label.

Proposals should address all of the following activities:

  • Perform a mapping of existing data quality and utility principles/initiatives/frameworks (i.e. EMA/HMA Big Data Stakeholders Group Data quality efforts, TEHDAS Data Quality Working Group[3], EOSC-LIFE[4] Health Data Research UK’s data quality and utility framework[5], and relevant data principles, resources and tools (FAIR, FAIR Cookbook, etc.)[6];
  • Conduct various stakeholder consultations, integrating all relevant data users and data holders of health data, EHDS Health Data Access Bodies (HDABs) and other relevant actors to validate data user needs and adequately take into account relevant initiatives when developing the proposed framework;
  • Develop a framework (set of technical specifications) for the data quality and utility label that supports the implementation of the EHDS legal provisions and the roll out of the label by the data holders and EHDS Health Data Access Bodies;
  • Pilot and evaluate the use of the proposed framework (as a label and as a maturity model) on a datasets sample representing the wide-ranging data types (such as electronic health records, genomics datasets, medical registries, administrative data, etc.) and taking into account the needs of all data users identified.
  • Develop recommendations for the successful implementation and adoption of the data quality and utility label and maturity model across European Member States considering the maturity levels regarding secondary of health data.

The consortium should be composed of representatives from data users, data holders, health data access bodies, and other relevant stakeholders to the scope of secondary use of health data, adequately covering the diversity of heath data types and users’ needs across European Member States.

[1] https://b1mg-project.eu/work-packages/wp3

[2] https://www.ema.europa.eu/en/about-us/how-we-work/big-data

[3] https://tehdas.eu/packages/

[4]https://www.eosc-life.eu/

[5]Development of a data utility framework to support effective health data curation: https://informatics.bmj.com/content/28/1/e100303?utm_source=twitter&utm_medium=social&utm_term=hootsuite&utm_content=sme&utm_campaign=usage

[6]See definition of FAIR data in the introduction to this work programme part.

Eligibility

General conditions

  1. Admissibility conditions: described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.

Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.

  1. Eligible countries: described in Annex B of the Work Programme General Annexes.

A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide .

  1. Other eligibility conditions: described in Annex B of the Work Programme General Annexes.

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America may exceptionally participate as a beneficiary or affiliated entity, and are eligible to receive Union funding.

Coordinators of projects must be legal entities established in an EU Member State or Associated Country.

  1. Financial and operational capacity and exclusion: described in Annex C of the Work Programme General Annexes.

  2. Evaluation and award:

Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.

The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.

Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual .

Indicative timeline for evaluation and grant agreement: described in Annex F of the Work Programme General Annexes.

  1. Legal and financial set-up of the grants: described in Annex G of the Work Programme General Annexes.

Specific conditions

  1. Specific conditions: described in the specific topic of the Work Programme .

Documents

Call documents:

Standard application form (HE CSA) - call-specific application form is available in the Submission System Standard evaluation form (HE CSA) HE General MGA v1.0 Information on clinical studies (HE)

Additional documents:

HE Main Work Programme 2023–2024 – 1. General Introduction HE Main Work Programme 2023–2024 – 4. Health HE Main Work Programme 2023–2024 – 13. General Annexes

HE Programme Guide HE Framework Programme and Rules for Participation Regulation 2021/695 HE Specific Programme Decision 2021/764 EU Financial Regulation Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment EU Grants AGA — Annotated Model Grant Agreement Funding & Tenders Portal Online Manual Funding & Tenders Portal Terms and Conditions Funding & Tenders Portal Privacy Statement

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
20 April 2023